Connect with us

Healthcare

Suven Life Sciences Limited (suven) to Present Clinical Progress at Ctad-2026

Suven Life Sciences Limited (SUVEN) to present Masupirdine and Tenaclidine clinical data at CTAD-2026.

Deputy Editor, Equities for tradealone

Published

on

Suven Life Sciences Limited SUVEN Ctad-2026

Suven Life Sciences Limited (NSE: SUVEN), a clinical-stage biopharmaceutical company, announced its participation in the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, USA. The company will present two scientific presentations highlighting the clinical progress of its investigational drug candidates, Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107).

Masupirdine Phase-3 Baseline Demographic & Clinical Characteristics

The first presentation, P033, will cover the baseline demographic and clinical characteristics of patients enrolled in the global Phase-3 study of Masupirdine. This study targets agitation in patients with dementia of Alzheimer’s type. The completion of enrollment marks a significant milestone in the clinical development, with baseline characteristics consistent with published studies.

Tenaclidine Phase-1 First-In-Human Safety

The second presentation, P066, will focus on the outcome from the Phase-1 studies of Tenaclidine in healthy subjects. This includes safety, tolerability, and pharmacokinetics, as well as the effects of food, age, and gender on its pharmacokinetic profile. The progress reflects Suven’s continued efforts to advance innovative therapeutic approaches addressing significant unmet needs in CNS disorders.

Forward-Looking Statements

Mr. Venkat Jasti, Chairman and Managing Director, expressed optimism about the clinical findings for Tenaclidine and the upcoming topline results for Masupirdine in Q2-2027. However, the company notes that all statements may involve risks and uncertainties, and it may not update any forward-looking statements.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Suven Life Sciences Limited

Suven Life Sciences Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

SUVEN
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING DOWN
32
Fundamental
76
Technical
55
Overall

1W +4.89%
1M -2.68%
3M -18.85%
Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Suven falls 18.9% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 5 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 55% of its 52-week range with RSI at 38. In other words, neither side has a clear edge right now. The stock holds up despite -19.3% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Suven Life Sciences Limited.

BIOCON

Biocon Limited Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection

Biocon Limited (BIOCON) receives U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, expanding its oncology portfolio.

kuldeep yadav tradealone

Published

on

Biocon Limited Biocon FDA Approval Pebrilzo

Biocon Limited (BIOCON) announced today that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo™ (pertuzumab-qcay), a biosimilar of the reference product Perjeta®. This marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. Pebrilzo™ is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio, now totaling five biosimilar therapies for cancer in the United States.

Expanding Access to Affordable Biologics

Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “The U.S. FDA approval of Pebrilzo™, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, Pebrilzo™ strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.”

Strengthening Oncology Portfolio

Pebrilzo™ will join Biocon’s robust portfolio of oncology therapies, which includes Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb), and Aukelso® (denosumab-kyqq). Building on this foundation, Biocon’s growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab, and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.

As a result, Biocon’s oncology strategy combines an established portfolio with continued development across additional treatment approaches, addressing the ongoing need for treatment options in this area.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
—
52
Fundamental
56
Technical
54
Overall

1W -0.29%
1M +3.84%
3M -12.7%
P/E: 122.2 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon falls 12.7% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 3.8% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

Healthcare

Themis Medicare Limited (themismed) Q2 FY27: Revenue Up 15%, Ebitda Positive

Themis Medicare Limited (THEMISMED) reports a 15% revenue increase in Q2 FY27, with EBITDA turning positive at 6.2% margin.

shalini shishodia tradealone

Published

on

Themis Medicare Limited Themismed Q2 FY27 Results

Themis Medicare Limited (THEMISMED) has announced its financial results for Q2 FY27, showcasing a strong turnaround with a 15.1% year-on-year revenue growth to ₹89.74 crore. This performance was led by a remarkable 71% rebound in the API business to ₹20 crore, while the Formulations business maintained steady revenue at ₹69 crore.

Financial Highlights

The company reported a return to operating profitability with an EBITDA of ₹5.58 crore at a 6.2% margin, compared to a loss in the year-ago quarter. The net profit after tax (PAT) stood at ₹7.06 crore against a loss last year. This improvement is attributed to the company’s focus on productivity and operational efficiency.

Segment Performance

Within Formulations, the Critical Care Division doubled its profit before tax (PBT) during the quarter, driven by Themiseal Gel’s encouraging month-on-month momentum. The Ortho and Gynecology Division also doubled its revenue, bolstered by strong traction in the hormonal portfolio and the integrated product strategy. The API business demonstrated a robust recovery, gaining healthy revenue visibility.

For H1 FY27, revenue stood at ₹176.70 crore, with the strong performance in Q2 helping offset a more challenging first quarter. The company remains optimistic about the second half of the year, supported by continued operational efficiencies, stronger field productivity, disciplined cost management, and a sustained recovery in the API business.

Dr. Sachin Patel, Managing Director & CEO, commented, “Q2 FY27 reflects a strong turnaround for the Company. We are pleased to report a return to operating profitability, with EBITDA of ₹5.58 crore at a 6.2% margin, compared with a loss in the year-ago quarter, and PAT of ₹7.06 crore against a loss last year. This improvement comes even as we continue to optimize our inventory pricing and cost structure and gives us confidence that our focus on productivity and operational efficiency is delivering results.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Themis Medicare Limited

Themis Medicare Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

THEMISMED
Healthcare › Drug Manufacturers - Specialty & Generic
APPROACHING SUPPORT
36
Fundamental
44
Technical
40
Overall

1W -0.35%
1M -6.69%
3M -3.77%
P/E: 23.3 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Themis moves sideways over three months, with neither buyers nor sellers taking control. Revenue contracts at -0.4% CAGR. That signals structural headwinds, not a short-term blip. No meaningful dividend — total return is entirely dependent on capital appreciation. RSI stands at 31, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at -0.4% yet the PEG reaches 99.00 — expensive for that growth. Furthermore, the stock drops 3.8% in three months. Neither value nor momentum supports this setup. It needs an earnings beat or a price reset first. Check Fundamentals of Themis Medicare Limited.

Continue Reading

GUJTHEM

Gujarat Themis Biosyn Limited Q2 FY27: Revenue Up 12% Yoy, New Facility Commissioned

Gujarat Themis Biosyn Limited (GUJTHEM) reports Q2 FY27 revenue up 12% YoY, new fermentation facility commissioned.

shalini shishodia tradealone

Published

on

Gujarat Themis Biosyn Limited Gujthem Q2 FY27 Results

Gujarat Themis Biosyn Limited (GUJTHEM) has reported robust financial results for Q2 FY27, with standalone revenue growing 12% year-on-year to Rs. 47.5 crore. The growth was primarily driven by strong volume momentum and a favorable shift in product mix towards Active Pharmaceutical Ingredients (APIs). The company’s new fermentation facility, commissioned during the quarter, marks a significant milestone in strengthening its manufacturing capabilities. Although the commissioning phase has had a near-term impact on operating margins, benefits from augmented capacity utilization are expected to become increasingly visible from Q4 FY27 onwards.

Quarterly Financial Highlights

During Q2 FY27, the company’s EBITDA stood at Rs. 8.5 crore, down 15.3% year-on-year, while EBITDA margins decreased by 1,210 basis points to 17.8%. The profit after tax (PAT) was Rs. 8.5 crore, down 40.6% YoY, with PAT margins dropping by 1,584 basis points to 17.8%. The company’s earnings per share (EPS) stood at Rs. 0.65 compared to Rs. 1.31 in the same quarter last year.

Half-Yearly Financial Performance

For H1 FY27, the company’s revenue grew 17% year-on-year to Rs. 91 crore. EBITDA increased 11% to Rs. 39 crore, while EBITDA margins declined by 235 basis points to 42.2%. The PAT for H1 FY27 was Rs. 19.5 crore, down 16.3% YoY, with PAT margins decreasing by 841 basis points to 21.4%. The EPS for H1 FY27 was Rs. 1.50 compared to Rs. 2.14 in the same period last year.

Dr. Sachin Patel, Managing Director, commented on the results, stating, ‘We are pleased to have commenced FY27 with healthy business momentum. As the new capacity moves towards higher utilization and the benefits of the acquisition begin to flow through, we expect operating performance to strengthen progressively. Our strategic priorities remain centered around precision fermentation, bioconversion, gene therapy, anti-infectives, and biopeptides, supported by capacity utilization, R&D-led product development, and a continued focus on operational efficiency. We believe these initiatives provide a strong platform for sustainable growth and value creation over the medium to long term.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Gujarat Themis Biosyn Limited

Gujarat Themis Biosyn Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

GUJTHEM
Healthcare › Drug Manufacturers - Specialty & Generic
CONSOLIDATING UP
52
Fundamental
60
Technical
56
Overall

1W +2.22%
1M -0.13%
3M +11.44%
P/E: 86.2 Cap: Mid
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Gujarat posts a 11.4% three-month gain, but softens in the last few weeks. Industry-leading margins of 28.0% reflect exceptional pricing power and operational efficiency. Revenue contracts at 3.8% CAGR. That signals structural headwinds, not a short-term blip. The stock gives back 0.1% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Revenue grows at 3.8% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Gujarat Themis Biosyn Limited.

Continue Reading

Trending

Exit mobile version